Pharma BD Deal Intelligence
Boston Scientific makes $4.2B offer to buy BTG and build out its oncology and vascular franchises with minimally invasive cancer and vascular treatments.
Boston Scientific closes acquisition of BTG plc on August 20 2019 completing its second largest acquisition ever after the $26B Guidant purchase.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Boston Scientific acquired BTG plc for approximately $4.2 billion in cash. The acquisition expanded Boston Scientific's interventional medicine portfolio, particularly in interventional oncology and vascular therapies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boston Scientific Corporation / BTG plc (this deal) | 2018 | $4.2B | 78 |
| Boston Scientific Corporation / Endo International plc (American Medical Systems Men's Health and Prostate Health) | 2015 | $1.6B | 82 |
| Boston Scientific Corporation / Advanced Bionics Corporation | 2004 | $740M | 26 |
| Boston Scientific Corporation / Vertiflex, Inc. | 2019 | $465M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2018 deals · Boston Scientific Corporation deals · Oncology deals